Literature DB >> 29606505

Prevention of Photoreceptor Cell Loss in a Cln6nclf Mouse Model of Batten Disease Requires CLN6 Gene Transfer to Bipolar Cells.

Sophia-Martha Kleine Holthaus1, Joana Ribeiro2, Laura Abelleira-Hervas2, Rachael A Pearson2, Yanai Duran2, Anastasios Georgiadis2, Robert D Sampson2, Matteo Rizzi2, Justin Hoke2, Ryea Maswood2, Selina Azam2, Ulrich F O Luhmann2, Alexander J Smith2, Sara E Mole3, Robin R Ali4.   

Abstract

The neuronal ceroid lipofuscinoses (NCLs) are inherited lysosomal storage disorders characterized by general neurodegeneration and premature death. Sight loss is also a major symptom in NCLs, severely affecting the quality of life of patients, but it is not targeted effectively by brain-directed therapies. Here we set out to explore the therapeutic potential of an ocular gene therapy to treat sight loss in NCL due to a deficiency in the transmembrane protein CLN6. We found that, although Cln6nclf mice presented mainly with photoreceptor degeneration, supplementation of CLN6 in photoreceptors was not beneficial. Because the level of CLN6 is low in photoreceptors but high in bipolar cells (retinal interneurons that are only lost in Cln6-deficient mice at late disease stages), we explored the therapeutic effects of delivering CLN6 to bipolar cells using adeno-associated virus (AAV) serotype 7m8. Bipolar cell-specific expression of CLN6 slowed significantly the loss of photoreceptor function and photoreceptor cells. This study shows that the deficiency of a gene normally expressed in bipolar cells can cause the loss of photoreceptors and that this can be prevented by bipolar cell-directed treatment.
Copyright © 2018 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AAV gene therapy; Batten disease; bipolar cells; lysosomal storage disorders; neuronal ceroid lipofuscinoses; photoreceptors; retina

Mesh:

Substances:

Year:  2018        PMID: 29606505      PMCID: PMC5993939          DOI: 10.1016/j.ymthe.2018.02.027

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  43 in total

1.  Present Molecular Limitations of ON-Bipolar Cell Targeted Gene Therapy.

Authors:  Michiel van Wyk; Elmar C Hulliger; Lara Girod; Andreas Ebneter; Sonja Kleinlogel
Journal:  Front Neurosci       Date:  2017-03-29       Impact factor: 4.677

2.  Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouse.

Authors:  Hanlin Gao; Rose-Mary N Boustany; Janice A Espinola; Susan L Cotman; Lakshmi Srinidhi; Kristen Auger Antonellis; Tammy Gillis; Xuebin Qin; Shumei Liu; Leah R Donahue; Roderick T Bronson; Jerry R Faust; Derek Stout; Jonathan L Haines; Terry J Lerner; Marcy E MacDonald
Journal:  Am J Hum Genet       Date:  2001-12-21       Impact factor: 11.025

3.  Next generation sequencing-based molecular diagnosis of retinitis pigmentosa: identification of a novel genotype-phenotype correlation and clinical refinements.

Authors:  Feng Wang; Hui Wang; Han-Fang Tuan; Duy H Nguyen; Vincent Sun; Vafa Keser; Sara J Bowne; Lori S Sullivan; Hongrong Luo; Ling Zhao; Xia Wang; Jacques E Zaneveld; Jason S Salvo; Sorath Siddiqui; Louise Mao; Dianna K Wheaton; David G Birch; Kari E Branham; John R Heckenlively; Cindy Wen; Ken Flagg; Henry Ferreyra; Jacqueline Pei; Ayesha Khan; Huanan Ren; Keqing Wang; Irma Lopez; Raheel Qamar; Juan C Zenteno; Raul Ayala-Ramirez; Beatriz Buentello-Volante; Qing Fu; David A Simpson; Yumei Li; Ruifang Sui; Giuliana Silvestri; Stephen P Daiger; Robert K Koenekoop; Kang Zhang; Rui Chen
Journal:  Hum Genet       Date:  2013-10-24       Impact factor: 4.132

4.  In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous.

Authors:  Deniz Dalkara; Leah C Byrne; Ryan R Klimczak; Meike Visel; Lu Yin; William H Merigan; John G Flannery; David V Schaffer
Journal:  Sci Transl Med       Date:  2013-06-12       Impact factor: 17.956

5.  Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous.

Authors:  Deniz Dalkara; Kathleen D Kolstad; Natalia Caporale; Meike Visel; Ryan R Klimczak; David V Schaffer; John G Flannery
Journal:  Mol Ther       Date:  2009-08-11       Impact factor: 11.454

6.  Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial.

Authors:  Nicola G Ghazi; Emad B Abboud; Sawsan R Nowilaty; Hisham Alkuraya; Abdulrahman Alhommadi; Huimin Cai; Rui Hou; Wen-Tao Deng; Sanford L Boye; Abdulrahman Almaghamsi; Fahad Al Saikhan; Hassan Al-Dhibi; David Birch; Christopher Chung; Dilek Colak; Matthew M LaVail; Douglas Vollrath; Kirsten Erger; Wenqiu Wang; Thomas Conlon; Kang Zhang; William Hauswirth; Fowzan S Alkuraya
Journal:  Hum Genet       Date:  2016-01-29       Impact factor: 4.132

7.  Progressive retinal degeneration and glial activation in the CLN6 (nclf) mouse model of neuronal ceroid lipofuscinosis: a beneficial effect of DHA and curcumin supplementation.

Authors:  Myriam Mirza; Cornelia Volz; Marcus Karlstetter; Monica Langiu; Aleksandra Somogyi; Mika O Ruonala; Ernst R Tamm; Herbert Jägle; Thomas Langmann
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

8.  Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors.

Authors:  Christine N Kay; Renee C Ryals; George V Aslanidi; Seok Hong Min; Qing Ruan; Jingfen Sun; Frank M Dyka; Daniel Kasuga; Andrea E Ayala; Kim Van Vliet; Mavis Agbandje-McKenna; William W Hauswirth; Sanford L Boye; Shannon E Boye
Journal:  PLoS One       Date:  2013-04-26       Impact factor: 3.240

9.  Tyrosine capsid-mutant AAV vectors for gene delivery to the canine retina from a subretinal or intravitreal approach.

Authors:  F M Mowat; K R Gornik; A Dinculescu; S L Boye; W W Hauswirth; S M Petersen-Jones; J T Bartoe
Journal:  Gene Ther       Date:  2013-11-14       Impact factor: 5.250

10.  Non-invasive assessment of retinal alterations in mouse models of infantile and juvenile neuronal ceroid lipofuscinosis by spectral domain optical coherence tomography.

Authors:  Janos Groh; David Stadler; Mathias Buttmann; Rudolf Martini
Journal:  Acta Neuropathol Commun       Date:  2014-05-10       Impact factor: 7.801

View more
  14 in total

1.  Structure comparison of the chimeric AAV2.7m8 vector with parental AAV2.

Authors:  Antonette Bennett; Annahita Keravala; Victoria Makal; Justin Kurian; Brahim Belbellaa; Rangoli Aeran; Yu-Shan Tseng; Duncan Sousa; John Spear; Mehdi Gasmi; Mavis Agbandje-McKenna
Journal:  J Struct Biol       Date:  2019-12-16       Impact factor: 2.867

2.  Gene Therapy Targeting the Inner Retina Rescues the Retinal Phenotype in a Mouse Model of CLN3 Batten Disease.

Authors:  Sophia-Martha Kleine Holthaus; Mikel Aristorena; Ryea Maswood; Olha Semenyuk; Justin Hoke; Aura Hare; Alexander J Smith; Sara E Mole; Robin R Ali
Journal:  Hum Gene Ther       Date:  2020-07       Impact factor: 5.695

Review 3.  Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy.

Authors:  Nicola Specchio; Alessandro Ferretti; Marina Trivisano; Nicola Pietrafusa; Chiara Pepi; Costanza Calabrese; Susanna Livadiotti; Alessandra Simonetti; Paolo Rossi; Paolo Curatolo; Federico Vigevano
Journal:  Drugs       Date:  2021-01       Impact factor: 9.546

Review 4.  Therapeutic landscape for Batten disease: current treatments and future prospects.

Authors:  Tyler B Johnson; Jacob T Cain; Katherine A White; Denia Ramirez-Montealegre; David A Pearce; Jill M Weimer
Journal:  Nat Rev Neurol       Date:  2019-03       Impact factor: 42.937

5.  Advances in the Treatment of Neuronal Ceroid Lipofuscinosis.

Authors:  Jonathan B Rosenberg; Alvin Chen; Stephen M Kaminsky; Ronald G Crystal; Dolan Sondhi
Journal:  Expert Opin Orphan Drugs       Date:  2019-11-27       Impact factor: 0.694

Review 6.  Current and Emerging Treatment Strategies for Neuronal Ceroid Lipofuscinoses.

Authors:  Alfried Kohlschütter; Angela Schulz; Udo Bartsch; Stephan Storch
Journal:  CNS Drugs       Date:  2019-04       Impact factor: 5.749

7.  Mice deficient in the lysosomal enzyme palmitoyl-protein thioesterase 1 (PPT1) display a complex retinal phenotype.

Authors:  Yevgeniya Atiskova; Susanne Bartsch; Tatyana Danyukova; Elke Becker; Christian Hagel; Stephan Storch; Udo Bartsch
Journal:  Sci Rep       Date:  2019-10-02       Impact factor: 4.379

8.  Intracranial delivery of AAV9 gene therapy partially prevents retinal degeneration and visual deficits in CLN6-Batten disease mice.

Authors:  Katherine A White; Hemanth R Nelvagal; Timothy A Poole; Bin Lu; Tyler B Johnson; Samantha Davis; Melissa A Pratt; Jon Brudvig; Ana B Assis; Shibi Likhite; Kathrin Meyer; Brian K Kaspar; Jonathan D Cooper; Shaomei Wang; Jill M Weimer
Journal:  Mol Ther Methods Clin Dev       Date:  2021-01-05       Impact factor: 6.698

Review 9.  Gene Therapy for Lysosomal Storage Disorders: Ongoing Studies and Clinical Development.

Authors:  Giulia Massaro; Amy F Geard; Wenfei Liu; Oliver Coombe-Tennant; Simon N Waddington; Julien Baruteau; Paul Gissen; Ahad A Rahim
Journal:  Biomolecules       Date:  2021-04-20

10.  Rapid and Progressive Loss of Multiple Retinal Cell Types in Cathepsin D-Deficient Mice-An Animal Model of CLN10 Disease.

Authors:  Mahmoud Bassal; Junling Liu; Wanda Jankowiak; Paul Saftig; Udo Bartsch
Journal:  Cells       Date:  2021-03-21       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.